CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.
September 7, 2018
Vice President & Head for Cardiovascular & Metabolic Disease, Partnering & Strategy
One MedImmune Way
Gaithersburg, MD 20878
Re: Amendment No. 6 to Sub-Licence and Collaboration Agreement
As you know, Humabs Biomed SA (Humabs), a wholly owned subsidiary of Vir Biotechnology Inc., and MedImmune, LLC (MedImmune) are parties to that certain Sub-Licence and Collaboration Agreement dated March 20, 2012, as amended (the Agreement). By this letter amendment (this Amendment), Humabs and MedImmune agree to amend the Agreement as described below, effective as of the date first set forth above.
Subclause (i) of Section 2.4 of the Agreement, as amended by Amendment No. 4 to the Sub-Licence and Collaboration Agreement, is hereby amended and replaced in its entirety to read as follows:
Clause 9.7.2 of the Agreement is hereby amended and replaced in its entirety to read as follows:
A Receiving Party may disclose the existence and terms of this Agreement and the Confidential Information of the Disclosing Party to its attorneys and advisors and to potential acquirers in connection with a potential consolidation, acquisition, merger or similar transaction and to existing and potential investors or lenders of the Receiving Party, as a part of their due diligence investigations, and/or to potential licensees and/or to potential collaborators and/or to permitted assignees, in each case under a written agreement to keep